Aurinia Pharmaceuticals Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $407.8M | $272.4M |
| FY2021 | — | $479.1M | $231.6M |
| FY2022 | — | $405.4M | $94.1M |
| FY2023 | — | $378.0M | $48.8M |
| FY2024 | — | $377.5M | $83.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $407.8M | $272.4M |
| FY2021 | — | $479.1M | $231.6M |
| FY2022 | — | $405.4M | $94.1M |
| FY2023 | — | $378.0M | $48.8M |
| FY2024 | — | $377.5M | $83.4M |